Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E-mutant Metastatic Colorectal Cancer”

12 trials

Showing 12 of 12 results

Large-scale testing (Phase 3)Study completedNCT02928224
What this trial is testing

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutant Metastatic Colorectal Cancer
Pfizer 702
Not applicableNot Yet RecruitingNCT07007689
What this trial is testing

A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer

Who this might be right for
BRAF V600E-mutant Metastatic Colorectal Cancer
Sun Yat-sen University 200
Large-scale testing (Phase 3)Looking for participantsNCT06008119
What this trial is testing

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc. 165
Testing effectiveness (Phase 2)Study completedNCT03693170
What this trial is testing

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Who this might be right for
BRAF V600E-mutant Metastatic Colorectal Cancer
Pierre Fabre Medicament 95
Testing effectiveness (Phase 2)Active Not RecruitingNCT05217446
What this trial is testing

Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 107
Not applicableStudy completedNCT01437618
What this trial is testing

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Azienda Ospedaliero, Universitaria Pisana 15
Testing effectiveness (Phase 2)Study completedNCT05004350
What this trial is testing

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Who this might be right for
BRAF V600EMetastatic Colorectal Cancer
Pierre Fabre Medicament 107
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178717
What this trial is testing

Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

Who this might be right for
Colo-rectal Cancer
Vall d'Hebron Institute of Oncology 25
Large-scale testing (Phase 3)Active Not RecruitingNCT04607421
What this trial is testing

Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Who this might be right for
Neoplasms
Pfizer 831
Testing effectiveness (Phase 2)Study completedNCT04790448
What this trial is testing

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 37
Testing effectiveness (Phase 2)Looking for participantsNCT07150247
What this trial is testing

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600 Colorectal Cancer
Sun Yat-sen University 20
Not applicableStudy completedNCT04317599
What this trial is testing

A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

Who this might be right for
BRAF V600E Mutation PositiveMetastatic Colorectal Cancer
Pierre Fabre Medicament 274

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation